Adheris Health Advances AI-Driven Growth Amid Cost Cuts and Revenue Shift

Revenue Growth and Margin Pressure

Adheris Health (ASX:AHE) posted Q3 FY26 revenue of $9.4 million, marking a $1.7 million increase over the same quarter last year. However, gross margin contracted by 8 percentage points to 39.7%, reflecting ongoing cost pressures and timing mismatches in abatement payments. Gross profit stood at $2.1 million, up $1.3 million year-on-year, while operating cash flow remained negative at $0.2 million for the quarter. The company is actively working to normalise cash flow timing and expects to achieve cashflow neutrality by Q4 FY26.

This operational momentum follows a period of sharper revenue declines and restructuring, including leadership changes and cost reductions, as detailed in the company’s earlier cost-cutting initiatives and AI strategy and a challenging Q2 FY26 performance amid revenue drop.

Technology Platform Enhancements and AI Integration

Adheris is investing heavily in its digital platform, with several upgrades rolled out in Q3 and a substantial release scheduled for Q4. Enhancements include more precise program sizing, improved user interface and experience for staff, and increased configurability of digital programs. The upcoming release will add support for more complex program types, expanded THRiV and digital capabilities, advanced reporting, and improved program monitoring and alerting.

These technology improvements aim to shorten sales cycles, accelerate go-live times, and reduce delivery costs. The company is also piloting AI-powered productivity tools such as ChatGPT and Claude to boost internal efficiency and reduce manual effort, a continuation of its broader strategy to leverage AI for patient engagement and operational scalability.

Shifting Revenue Mix and Growth in Specialty Categories

Adheris is actively diversifying its revenue base away from vaccines, which historically dominated its income, towards higher-growth and higher-margin categories like obesity (notably GLP-1 medications), immunology, diabetes, respiratory, and complex specialty conditions. Non-vaccine revenue now accounts for 82% of total revenue year-to-date FY26, up from 64% in FY25.

The company highlighted measurable momentum in GLP-1 programs, with $1.7 million revenue YTD FY26 compared to $1.4 million in FY25 and a projected compound annual growth rate of around 15% over the next three years. Additionally, Adheris is re-engaging lost pharmaceutical brands, securing $1.8 million in new win-back contracts and adding 10 new brands in the last two quarters, signalling a broadening pipeline across growth categories.

Expanding Pharmacy Network and Digital Connectivity

Adheris boasts the largest pharmacy network in the US, with about 170 million patients and over 25,000 pharmacies. The company is expanding its digital regulatory product footprint, with 2,064 stores live, 1,472 stores actively contracting, and an 8,060 store pipeline. The digital network footprint grew by 13.5 million new patients in Q3 FY26 alone.

Two regional chains are currently onboarding, and two national chain partners are enabling new program types and upsell potential. The company is also broadening its channel expansion opportunities by adding in-pharmacy and digital capabilities with large partners, aiming to grow beyond direct mail and create incremental revenue streams.

Cost Reduction and Leadership Alignment

Adheris is executing a substantial cost-out program, with annualised staff costs expected to fall from $22 million in FY25 to approximately $14.5 million, reflecting a leaner and more scalable operation. The leadership team’s compensation is increasingly performance-based, emphasising equity upside over fixed salaries and cash bonuses, aligning management incentives with shareholder value creation.

Internal adoption of AI tools is targeted at faster execution and higher output per full-time equivalent, supporting productivity gains. The company expects the full benefits of its cost-out program to materialise in Q4 FY26, coinciding with its goal of achieving cashflow neutrality.

Positioning for Profitable Growth in a Large Market

Adheris positions itself as an undervalued leader with a trusted 30+ year history in the US pharmacy and pharma sectors, operating in a sizeable addressable market estimated at around US$1 billion. Its next-generation platform is designed for rapid product rollout, improved customer experience, and operational efficiency, with architecture supporting expansion into new markets and channels.

Strategic groundwork is underway ahead of the late calendar year 2026 contracting season to capture a greater share of pharma budgets. The company’s disciplined capital allocation and cost management underpin a clear path back to growth and profitability.

Notably, the company’s recent financial progress builds on the final $6.1 million holdback payment received from its ANZ business sale earlier this year, which added to its liquidity position and supported its transformation efforts final holdback payment.